Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsORALGeneric

SERENTIL

MESORIDAZINE BESYLATE

Standard Dose
EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued

Key Takeaways

  • Primary indication: Review priority: STANDARD Marketing status: Discontinued
  • Approval overview SERENTIL is listed in Drugs@FDA under application 016774 (NDA).
  • Review priority: STANDARD Marketing status: Discontinued Active ingredient MESORIDAZINE BESYLATE Form and strength TABLET;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2001-07-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview SERENTIL is listed in Drugs@FDA under application 016774 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient MESORIDAZINE BESYLATE Form and strength TABLET;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2001-07-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.